ClinicalTrials.gg
CompletedNCT00641745Updated Jun 22, 2015Results posted

Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia

A Phase 3 interventional study of Lurasidone HCl and Risperidone in Schizophrenia and Schizoaffective Disorder, sponsored by Sumitomo Pharma America, Inc.. Completed at 73 sites in 8 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-06-22.

Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
629
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing lurasidone in Schizophrenia — none open to participants now, none under way, none of them phase 3. lurasidone · Schizophrenia.

Enrollment
3rd of 39
629 · median 149
Started
2008
with 8 others
Phase 3
18 of 39
none open now
Registered
7th of 39
by date
Lead sponsor
23 of 39
Sumitomo Pharma America, Inc.

Among the 39 studies testing lurasidone in Schizophrenia, this one is the 3rd largest by enrollment, is one of 9 that started in 2008, is one of 18 in phase 3, and was the 7th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

None of the 39 studies testing lurasidone in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →

About lurasidone

lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 39 studies testing lurasidone in Schizophrenia as a file.
02

Study summary

Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is safe and tolerable long term among clinically stable patients. The study will also assess the long term effectiveness of lurasidone as compared to an active comparator.

03

Conditions studied

  • Schizophrenia
  • Schizoaffective Disorder

Keywords

  • Lurasidone
  • Schizophrenia
  • Latuda
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

To be eligible to enter the study, each patient must comply with the following inclusion criteria:

  • Subject is 18 to 75 years on the day of signing the consent form (age parameters may be restricted further per local requirements without protocol amendment).
  • Subject meets , 4th Edition (DSM-IV) criteria for a primary diagnosis of schizophrenia (including disorganized (295.10), paranoid (295.30), undifferentiated (295.90), catatonic (295.20), or residual (295.60) or schizoaffective disorder (295.70) subtypes.
  • Subject is not pregnant or nursing, and is not planning pregnancy within the projected duration of the study.
  • Subject will comply with the study procedures and outpatient visit requirements in the opinion of the investigator.
  • Subject voluntarily agrees to participate in the study by giving written .

Main Exclusion Criteria:

To be excluded from entering this study if they fulfil any of the criteria below:

  • Subject has a chronic organic disease of the central nervous system (other than schizophrenia).
  • Subject has current or history of, alcohol abuse/alcoholism or drug abuse/dependence within the last 6 months.
  • In the opinion of the investigator, the subject has any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study, or interfere with the subject's participation for the full duration of the study.
  • Subject has participated in a study with an compound or device within 30 days of signing informed consent.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
629 participants (actual)

Study arms

  • Experimental
    1

    Lurasidone

    Drug: Lurasidone HCl

  • Active comparator
    2

    Risperidone

    Drug: Risperidone

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events.

    Time frame: 12 months

07

Results

Posted Oct 6, 2011

Participant flow

Participant flow — Overall Study
MilestoneLurasidoneRisperidone
Started427202
Completed14789
Not completed280113

Outcome measures

PrimaryNumber of Participants With Adverse Events.
Time frame:
12 months
Reported as:
Number · participants
Number of Participants With Adverse Events.
participantsLurasidoneRisperidone
Number of Participants With Adverse Events.395189

Adverse events

Collected over 14 days post-study therapy. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lurasidone—46/419 (11%)349/419 (83.3%)
Risperidone—20/202 (9.9%)169/202 (83.7%)
Most frequent serious events
Showing 10 of 47
Most frequent serious events
EventLurasidoneRisperidone
Psychotic DisorderPsychiatric disorders12/4198/202
SchizophreniaPsychiatric disorders8/4193/202
Suicidal IdeationPsychiatric disorders2/4192/202
FallInjury, poisoning and procedural complications3/4190/202
AppendicitisInfections and infestations0/4191/202
DiverticulitisInfections and infestations0/4191/202
Urinary Tract InfectionInfections and infestations0/4191/202
Wrist FractureInjury, poisoning and procedural complications1/4191/202
AkathisiaNervous system disorders1/4191/202
DystoniaNervous system disorders1/4191/202
Most frequent other events
Showing 10 of 15
Most frequent other events
EventLurasidoneRisperidone
Weight IncreasedInvestigations39/41940/202
SomnolenceNervous system disorders57/41936/202
NauseaGastrointestinal disorders70/41922/202
InsomniaPsychiatric disorders66/41927/202
HeadacheNervous system disorders42/41930/202
SedationNervous system disorders61/41928/202
AkathisiaNervous system disorders60/41916/202
VomitingGastrointestinal disorders42/4197/202
AnxietyPsychiatric disorders38/41917/202
Weight DecreasedInvestigations31/4199/202

Baseline characteristics

Age, Continuous
Age, Continuous(years)LurasidoneRisperidoneTotal
Mean41.7 ± 11.341.6 ± 11.341.7 ± 11.3
Gender
Gender(participants)LurasidoneRisperidoneTotal
Female11776193
Male302126428
Region of Enrollment
Region of Enrollment(participants)LurasidoneRisperidoneTotal
United States279133412
Argentina241337
Brazil15924
Thailand13316
Croatia7512
Israel303
Chile19726
South Africa593291
08

Study locations

73 sites
  • K&S Professional Research Services LLC
    Little Rock, Arkansas 72201, United States
  • Woodland International Research Group, LLC
    Little Rock, Arkansas 72211, United States
  • South Coast Clinical Trials, Inc.
    Anaheim, California 92804, United States
  • Comprehensive NeuroScience, Inc. - Cerritos
    Cerritos, California 90703, United States
  • Clinical Innovations Inc.
    Costa Mesa, California 92626, United States
  • Collaborative Neuroscience Network Inc
    Garden Grove, California 92845, United States
  • University of Southern California
    Los Angeles, California 90033, United States
  • Excell Research
    Oceanside, California 92056, United States
  • University of California at Irvine Medical Center
    Orange, California 92868, United States
  • Pasadena Research Institute
    Pasadena, California 91107, United States
  • CNRI-Los Angeles, LLC
    Pico Rivera, California 90660, United States
  • Clinical Innovations Inc.
    Riverside, California 92506, United States
  • CNRI-San Diego LLC
    San Diego, California 92102, United States
  • UCSD, Outpatient Psychiatric Services
    San Diego, California 92103, United States
  • Clinical Innovations Inc.
    Santa Ana, California 92705, United States
  • Collaborative Neuroscience Network Inc
    Torrance, California 90502, United States
  • Comprehensive NeuroScience, Inc.
    Washington, District of Columbia 20016, United States
  • Fidelity Clinical Research Inc., c/o Segal Institute for Clinical Research
    North Miami, Florida 33161, United States
  • Fidelity Clinical Research Inc.
    North Miami, Florida 33161, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30308, United States
  • Northlake Medical Research Center
    Tucker, Georgia 30084, United States
  • Alexian Brothers Medical Center
    Hoffman Estates, Illinois 60169, United States
  • Lake Charles Clinical Trials
    Lake Charles, Louisiana 70601, United States
  • Sheppard Pratt Health System
    Baltimore, Maryland 21285, United States
  • Precise Research Center
    Flowood, Mississippi 39232, United States
  • St. Charles Psychiatric Associates - Midwest Research
    St. Charles, Missouri 63301, United States
  • St. Louis Clinical Trials
    St. Louis, Missouri 63118, United States
  • Creighton University
    Omaha, Nebraska 68131, United States
  • CRI Worldwide
    Willingboro, New Jersey 08046, United States
  • SUNY Downstate University
    Brooklyn, New York 11203, United States
  • Neurobehavioral Research Inc.
    Cedarhurst, New York 11516, United States
  • Manhattan Psychiatric Center
    New York, New York 10035, United States
  • Social Psychiatry Research Institute
    New York, New York 10454, United States
  • University of North Carolina at Chapel Hill
    Raleigh, North Carolina 27603, United States
  • Keystone Clinical Studies, LLC
    Norristown, Pennsylvania 19403, United States
  • CRI Worldwide
    Philadelphia, Pennsylvania 19139, United States
  • Research Strategies of Memphis LLC
    Memphis, Tennessee 38119, United States
  • Community Clinical Research, Inc.
    Austin, Texas 78754, United States
  • Pillar Clinical Research LLC
    Dallas, Texas 75243, United States
  • Claghorn-Lesem Research Clinic, Inc.
    Houston, Texas 77008, United States
  • Alliance Research Group
    Richmond, Virginia 23230, United States
  • Fundación para el Estudio y Tratamiento de las Enf. Mentales
    Capital Federal, BUE C1425AHP, Argentina
  • Clinica Privada Neuropsiquiatrica San Agustin
    La Plata, BUE 1900, Argentina
  • Resolution Psychopharmacology Research Institute
    Mendoza, MEN M5502HLE, Argentina
  • CIAP
    Rosario, SFE S2000QJI, Argentina
  • Sanatorio 'Prof. Leon S. Morra' S.A.
    Cordoba, X5009BIN, Argentina
  • Sanatorio Sao Paulo
    Salvador, BA 40301-500, Brazil
  • Hospital Espirita de Psiquiatria Bom Retiro
    Curitiba, PR 80520-000, Brazil
  • Hospital Mario Kroeff
    Rio de Janeiro, RJ 21020-130, Brazil
  • PAX Clinica Psiquiatrica Ltda
    Aparecida de Goiania, 74922-810, Brazil
  • Hospital Clincio Felix Bulnes
    Quinta Normal, Santiago, Chile
  • Instituto Psiquiátrico Dr. José Horwitz Barak
    Recoleta, Santiago, Chile
  • Hospital Barros Luco Trudeau
    San Miguel, Santiago, Chile
  • CIPAM - Clínica Pedro Montt
    Santiago, Chile
  • Hospital Base Valdivia
    Valdivia, Chile
  • Clinical Hospital Centre Rijeka
    Rijeka, 51 000, Croatia
  • Psychiatric Hospital Vrapce
    Zagreb, 10 090, Croatia
  • Croatian institute for brain research Neuron
    Zagreb, 10000, Croatia
  • Beer Ya'acov Mental Health Center
    Beer Yaakov, 70300, Israel
  • Rambam Health Care Campus
    Haifa, 31096, Israel
  • Shalvata Mental Health Center, Ward B
    Hod Hasharon, 45100, Israel
  • Shalvata Mental Health Center
    Hod Hasharon, 45100, Israel
  • Chaim Sheba Medical Center
    Ramat Gan, 52621, Israel
  • Oranje Hospital
    Bloemfontein, Free State 9301, South Africa
  • Rand Clinic
    Johannesburg, Gauteng 2198, South Africa
  • Private Practice
    Pretoria, Gauteng 0181, South Africa
  • Flexivest fourteen Research Centre
    Cape Town, W Cape 7535, South Africa
  • Cape Trial Centre
    Cape Town, 7530, South Africa
  • Crompton Medical Centre East
    Natal, 3600, South Africa
  • Weskoppies Hospital
    Pretoria West, 0001, South Africa
  • King Chulalongkorn Memorial Hospital
    Chulalongkorn University, Bangkok, Thailand
  • Somdet Chaopraya Institute of Psychiatry
    Klongsan, Bangkok, Thailand
  • Suan Prung Psychiatric Hospital
    Muang, Chiang Mai, Thailand
09

References and documents

Publications

  • Keefe RS, Fox KH, Harvey PD, Cucchiaro J, Siu C, Loebel A. Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial. Schizophr Res. 2011 Feb;125(2-3):161-8. doi: 10.1016/j.schres.2010.09.015. Epub 2010 Dec 31. PubMed 21075600 ↗
  • Citrome L, Cucchiaro J, Sarma K, Phillips D, Silva R, Tsuchiya S, Loebel A. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. Int Clin Psychopharmacol. 2012 May;27(3):165-76. doi: 10.1097/YIC.0b013e32835281ef. PubMed 22395527 ↗
  • Patel PJ, Weidenfeller C, Jones AP, Nilsson J, Hsu J. Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study. Neurol Ther. 2021 Jun;10(1):121-147. doi: 10.1007/s40120-020-00221-4. Epub 2020 Oct 24. PubMed 33098548 ↗
  • Mattingly GW, Haddad PM, Tocco M, Xu J, Phillips D, Pikalov A, Loebel A. Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study. BMC Psychiatry. 2020 May 5;20(1):199. doi: 10.1186/s12888-020-02523-1. PubMed 32370778 ↗
  • Georgiades A, Davis VG, Atkins AS, Khan A, Walker TW, Loebel A, Haig G, Hilt DC, Dunayevich E, Umbricht D, Sand M, Keefe RSE. Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patients. Schizophr Res. 2017 Dec;190:172-179. doi: 10.1016/j.schres.2017.03.040. Epub 2017 Apr 20. PubMed 28433500 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2008, a primary completion of Jul 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2011, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2008
First posted
Mar 24, 2008
Start
Mar 2008
Primary completionActual
Jul 2010
CompletionActual
Jul 2010
Results first posted
Oct 6, 2011
Last update
Jun 22, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00641745
Responsible party
Sponsor
First posted
Mar 24, 2008
Start date
Mar 2008
Primary completion
Jul 2010
Completion
Jul 2010
Results posted
Oct 6, 2011
Last update
Jun 22, 2015

Study contacts

Medical Director, MD
study director · Sumitomo Pharma America, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lurasidone

Start the discussion